Cantabio Announces Publication of Study Results by University of Cambridge researchers in ACS Chemical Neuroscience July 6, 2017
Cantabio Pharmaceuticals to Present Update from Its DJ-1 Protein Targeting Therapeutic Program for the Treatment of Parkinson's Disease at the 13th International Conference on Alzheimer's and Parkinson's Disease March 28, 2017
Cantabio Pharmaceuticals to Present at the 2nd Annual Neuroscience BioPartnering and Investment Forum at the New York Academy of Sciences in New York March 14, 2017
Cantabio Pharmaceuticals to Present Results from Its Tau Protein Targeting Therapeutic Program for the Treatment of Alzheimer's Disease at the 13th International Conference on Alzheimer's and Parkinson's Disease February 14, 2017
Cantabio Pharmaceuticals announces Definitive Funding Agreement of up to $600,000 from Yorkville Advisors Global February 2, 2017
Cantabio Pharmaceuticals to Present at the 9th Annual Biotech Showcase in San Francisco December 15, 2016
Cantabio Pharmaceuticals to Present at 2016 Silicon Valley Bank Healthcare Capital and Connections Summit in Shanghai September 19, 2016
Cantabio Pharmaceuticals licenses Tau protein targeting therapeutic program from University of Cambridge for the potential treatment of Alzheimer’s Disease and related Dementias September 7, 2016
Cantabio Pharmaceuticals to Present Results from its DJ-1 Protein Targeting Therapeutic Programs at the 4th World Parkinson’s Congress and 3rd International Parkinson’s Disease Symposium August 18, 2016
Cantabio Pharmaceuticals and Purdue Research Foundation Sign Cooperation Agreement to Investigate the Targeting of DJ-1 Protein for Treating Parkinson’s Disease and Other Neurodegenerative Diseases July 11, 2016